QL1706 Plus Chemotherapy±Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer
Clinical trial NCT05446883 · UNKNOWN
Trial details
- NCT number
- NCT05446883
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-09-23
- Primary completion
- 2024-09-01
- Enrollment
- 498
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.